19 October 2021 - Akero Therapeutics today announced that the U.S. FDA has granted fast track designation to its lead program investigating efruxifermin for the treatment of non-alcoholic steatohepatitis.
Akero's lead product candidate, efruxifermin is a differentiated Fc-FGF21 fusion protein that has been engineered to mimic the balanced biological activity profile of native FGF21, an endogenous hormone that alleviates cellular stress and regulates metabolism throughout the body.